News for ALKS Stock

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 Alkermes plc Reports First Quarter 2025 Financial Results New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) Alkermes to Report First Quarter Financial Results on May 1, 2025 Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder Alkermes to Participate in Upcoming Investor Conferences Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference Alkermes to Participate in Upcoming Investor Conferences Alkermes to Participate in Two Upcoming Investor Conferences Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences Alkermes plc Reports Third Quarter 2024 Financial Results Alkermes to Report Third Quarter Financial Results on October 24, 2024 Alkermes to Host Investor Event to Review Orexin Portfolio Strategy Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 Alkermes plc Reports Second Quarter 2024 Financial Results Alkermes to Report Second Quarter Financial Results on July 24, 2024 Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 Alkermes to Participate in Two Upcoming Investor Conferences Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk Alkermes plc Reports First Quarter 2024 Financial Results Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 Alkermes to Report First Quarter Financial Results on May 1, 2024 Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) Corporate Governance at Alkermes Alkermes' Commitment to Integrity and Compliance Alkermes' Culture of Employee Engagement and Wellness Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk Patient Advocacy and Community Engagement at Alkermes Pharmaceuticals in the Environment Alkermes to Participate in Two Upcoming Investor Conferences Environmental Protection & Sustainability at Alkermes Alkermes' Waste Optimization Highlights Alkermes Completes Separation of Oncology Business Our Commitment to Caregivers Product Stewardship and Environmental Impact at Alkermes Caring for Caregivers: Alkermes Celebrates National Caregivers Month Alkermes to Participate in the Jefferies London Healthcare Conference Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement Operating and Growing Responsibly at Alkermes Alkermes plc Reports Third Quarter 2023 Financial Results Alkermes CEO Reflects on Living Company Purpose Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress Alkermes to Report Third Quarter Financial Results on October 25, 2023 Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report Mural Oncology to Host Investor Webcast on October 17 Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month Alkermes Pathways Research Awards Is Now Accepting Applications! Alkermes Commemorates World Suicide Prevention Day Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program Alkermes to Participate in Two Upcoming Investor Conferences Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation Alkermes Honors Women's Equality Day Back to College? Talk to Your Student About Alcohol Alkermes plc Reports Second Quarter 2023 Financial Results Alkermes to Report Second Quarter Financial Results on July 26, 2023 Alkermes Celebrates Pride Month Celebrating 15 Years of Alkermes in Action Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders Juneteenth Reflections From Alkermes' Harold Weekes, Sr. Director, Human Resources Reflecting on Stigmas Surrounding Men’s Health During Men’s Health Week 2023 Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board Alkermes Participates in ALPFA’s Latina Summit Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation The Impact of Alkermes Inspiration Grants Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc Alkermes to Participate in Two Upcoming Investor Conferences Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process Alkermes Named Among Top 100 Companies Leading in Wellbeing by Ibec Alkermes Athlone Shortlisted for Gradirleand’s 17th Annual Graduate Recruitment Awards Alkermes Athlone Receives Award at Ireland’s 2023 Health & Safety Excellence Awards Alkermes Inspiration Grants Now Open for Applications Clinical Trials Integral to Providing More Treatment Options for Platinum-Resistant Ovarian Cancer (PROC) Alkermes plc Reports First Quarter 2023 Financial Results Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration Alkermes' Katie Joyce To Speak at Women in Bio 2023 Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program To Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer Alcohol Use Disorder Doesn’t Discriminate Alkermes to Report First Quarter Financial Results on April 26, 2023 Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business Alkermes Named to Ragan Communications and PR Daily’s Top Places To Work 2023 Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness Dr. Kevin Simon Shares Insights in Implicit Bias and Cultural Stigma Alkermes to Participate in the Stifel 2023 CNS Days Supporting Employees Beyond the Workplace – For Our People and for Our Business Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023 Alkermes' Company Culture Built On Foundation of Compassion, Science Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 Alkermes Celebrates Employee Volunteerism Throughout 2022 How Is the Brain Affected by Alcohol? Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference Alkermes to Participate in the Stifel Healthcare Conference Alkermes plc Reports Third Quarter 2022 Financial Results Alkermes plc Announces Intent to Separate Oncology Business Acorda Therapeutics Reports Third Quarter 2022 Financial Results Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022 Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress Alkermes plc Reports Second Quarter 2022 Financial Results Alkermes to Report Second Quarter Financial Results on July 27, 2022 Alkermes Announces Results of Annual General Meeting of Shareholders Sarissa Capital Comments on Alkermes Annual Meeting Alkermes to Participate in the Goldman Sachs Healthcare Conference Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer Alkermes to Participate in the Jefferies Healthcare Conference Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Sarissa Condemns Poor Corporate Governance at Alkermes Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Alkermes plc Reports First Quarter 2022 Financial Results Alkermes to Report First Quarter Financial Results on April 27, 2022 Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society Alkermes to Participate in the Stifel 2022 CNS Days Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022 Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022 Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders Alkermes to Take Part in the Stifel Virtual Healthcare Conference Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences Alkermes plc Reports Third Quarter 2021 Financial Results Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021 Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference New Survey Provides Insights Into Drinking Behaviors During the Pandemic Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma Alkermes plc Reports Second Quarter 2021 Financial Results Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021 Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference Alkermes Announces Agreement with Sarissa Capital Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting Alkermes plc Reports First Quarter 2021 Financial Results Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer Alkermes to Take Part in Stifel's 3rd Annual CNS Day Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma Alkermes to Hold Virtual Investor Day Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference Alkermes Announces Updates to Executive Leadership Team FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder Trading in Alkermes Ordinary Shares Halted Today Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience Alkermes to Take Part in Cantor Virtual Global Healthcare Conference Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020 Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results